Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
Phathom Pharmaceuticals (Nasdaq: PHAT) announced it will report third quarter 2025 financial results and provide a business update via live webcast on Thursday, October 30, 2025 at 8:00 AM EDT.
The live webcast and presentation materials will be available on the company's Events & Presentations page and a recording will be posted for 90 days after the call. Phathom develops gastrointestinal therapies and markets VOQUEZNA (vonoprazan) products in the U.S., including VOQUEZNA tablets for GERD and VOQUEZNA DUAL PAK/TRIPLE PAK for H. pylori treatment.
Media and investor contact details are provided for additional inquiries.
Phathom Pharmaceuticals (Nasdaq: PHAT) ha annunciato che riporterà risultati finanziari del terzo trimestre 2025 e fornirà un aggiornamento sull'attività tramite una trasmissione webcast in diretta giovedì 30 ottobre 2025 alle ore 8:00 EDT.
La trasmissione webcast in diretta e i materiali della presentazione saranno disponibili sulla pagina Eventi & Presentazioni dell'azienda e una registrazione sarà pubblicata per 90 giorni dopo la chiamata. Phathom sviluppa terapie gastrointestinali e commercializza prodotti VOQUEZNA (vonoprazan) negli Stati Uniti, inclusi VOQUEZNA tablet per GERD e VOQUEZNA DUAL PAK/TRIPLE PAK per il trattamento di H. pylori.
I contatti media e degli investitori sono forniti per ulteriori richieste.
Phathom Pharmaceuticals (Nasdaq: PHAT) anunció que informará resultados financieros del tercer trimestre de 2025 y proporcionará una actualización del negocio a través de una webcast en directo el jueves 30 de octubre de 2025 a las 8:00 AM EDT.
La webcast en directo y los materiales de la presentación estarán disponibles en la página de Eventos y Presentaciones de la empresa y se publicará una grabación durante 90 días después de la llamada. Phathom desarrolla terapias gastrointestinales y comercializa productos VOQUEZNA (vonoprazan) en los EE. UU., incluidas las tabletas VOQUEZNA para el GERD y VOQUEZNA DUAL PAK/TRIPLE PAK para el tratamiento de H. pylori.
Se proporcionan datos de contacto de prensa y de inversionistas para consultas adicionales.
Phathom Pharmaceuticals (나스닥: PHAT)은 2025년 3분기 재무 실적를 발표하고 사업 업데이트를 라이브 웹캐스트로 제공할 예정이며, 일정은 2025년 10월 30일 목요일 오전 8:00 EDT입니다.
라이브 웹캐스트 및 발표 자료는 회사의 이벤트 & 프리젠테이션 페이지에서 이용 가능하며, 방송은 통화 후 90일 동안 녹화본으로 게시됩니다. Phathom은 위장관 치료제를 개발하고 미국에서 VOQUEZNA(vonoprazan) 제품을 판매하며 GERD용 VOQUEZNA 정제 및 H. pylori 치료를 위한 VOQUEZNA DUAL PAK/TRIPLE PAK를 포함합니다.
추가 문의는 미디어 및 투자자 연락처를 통해 가능합니다.
Phathom Pharmaceuticals (Nasdaq : PHAT) a annoncé qu'il publiera les résultats financiers du troisième trimestre 2025 et fournira une mise à jour commerciale via une webcast en direct le jeudi 30 octobre 2025 à 8h00 EDT.
La webcast en direct et les supports de présentation seront disponibles sur la page Événements et Présentations de l'entreprise et un enregistrement sera publié pour 90 jours après l'appel. Phathom développe des thérapies gastro-intestinales et commercialise des produits VOQUEZNA (vonoprazan) aux États-Unis, y compris VOQUEZNA tablets pour le GERD et VOQUEZNA DUAL PAK/TRIPLE PAK pour le traitement de H. pylori.
Des coordonnées médias et investisseurs sont fournies pour des demandes supplémentaires.
Phathom Pharmaceuticals (Nasdaq: PHAT) gab bekannt, dass es die Finanzergebnisse des dritten Quartals 2025 berichten wird und via Live-Webcast ein Geschäftsupdate geben wird am Donnerstag, dem 30. Oktober 2025 um 8:00 Uhr EDT.
Der Live-Webcast und die Präsentationsmaterialien werden auf der Seite des Unternehmens "Events & Presentations" verfügbar sein und eine Aufzeichnung wird 90 Tage nach dem Call veröffentlicht. Phathom entwickelt gastrointestinale Therapien und vertreibt VOQUEZNA (vonoprazan) Produkte in den USA, einschließlich VOQUEZNA Tabletten für GERD und VOQUEZNA DUAL PAK/TRIPLE PAK für die Behandlung von H. pylori.
Medien- und Investorenkontakte stehen für weitere Anfragen bereit.
Phathom Pharmaceuticals (ناسداك: PHAT) أعلنت أنها ستبلغ عن النتائج المالية للربع الثالث من 2025 وتقديم تحديث عن الأعمال عبر بث مباشر على الويب يوم الخميس 30 أكتوبر 2025 الساعة 8:00 صباحاً بتوقيت شرق الولايات المتحدة.
سيكون البث المباشر ومواد العرض متاحة على صفحة فعاليات وعروض الشركة وسيتم نشر تسجيل لمدة 90 يوماً بعد المكالمة. طورت Phathom علاجات الجهاز الهضمي وتسوّق منتجات VOQUEZNA (vonoprazan) في الولايات المتحدة، بما في ذلك أقراص VOQUEZNA لـ GERD و VOQUEZNA DUAL PAK/TRIPLE PAK لعلاج H. pylori.
تفاصيل التواصل الإعلامي ومعلومات المستثمرين متاحة للإستفسارات الإضافية.
Phathom Pharmaceuticals (纳斯达克代码：PHAT)宣布将公布2025年第三季度财务业绩并通过现场网络广播提供业务更新，时间为2025年10月30日（星期四）美国东部夏令时8:00。
现场网络广播及演示材料将在公司“事件与演示”页面提供，且录制将在电话结束后90天内发布。Phathom开发胃肠道治疗药物，在美国市场销售 VOQUEZNA（vonoprazan）产品，其中包括用于GERD的 VOQUEZNA 片剂以及用于治疗H. pylori的 VOQUEZNA DUAL PAK/TRIPLE PAK。
如需更多咨询，请参阅媒体与投资者联系信息。
- None.
- None.
- Management to host conference call on Thursday, October 30, 2025, at 8:00 am EDT
FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, October 30, 2025, to report its third quarter 2025 financial results and provide a business update.
A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the call.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of the VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
FAQ
When will Phathom Pharmaceuticals (PHAT) report Q3 2025 results?
Where can investors watch the Phathom (PHAT) Q3 2025 webcast?
How long will the Phathom (PHAT) Q3 2025 call recording remain available?
What marketed products does Phathom Pharmaceuticals (PHAT) currently sell in the U.S.?
Who should media or investors contact about Phathom's Q3 2025 announcement?
